Navigation Links
Sermo, Inc. Introduces New Sponsorship Product for Pharma, Biotech and Life Sciences
Date:9/7/2011

CAMBRIDGE, Mass., Sept. 7, 2011 /PRNewswire/ -- Sermo, Inc. (www.sermo.com), the largest online physician network in the United States, today announced the launch of Sermo Sponsorship, a portfolio of offerings that provides new opportunities for pharmaceutical, biotechnology and life sciences companies to engage physicians and educate them on new products and programs. Sermo Sponsorship is available on both web and mobile platforms, where physicians across 68 specialties discuss top issues in healthcare and consult each other on clinical cases in order to provide the highest quality care to their patients.

(Logo: http://photos.prnewswire.com/prnh/20110713/NE34251LOGO-a)

Companies can use Sermo Sponsorship to drive awareness of drugs or devices or communicate new clinical and indication data.  The Sermo network facilitates discussion and peer influence, creating a multiplier effect that reinforces key takeaways and increases the number of physicians exposed to the new information.

"Whether companies are launching new treatments or sharing new data from clinical trials, Sermo Sponsorship enables them to reach, engage and influence the treatment decisions of their target specialists," said Jon Michaeli, Vice President of Marketing at Sermo. "Industry research shows that peer influence has the greatest impact on clinical decisions. Sermo's social platform makes it easy for physicians to share new industry developments with their colleagues."

According to the Manhattan Research study, Taking the Pulse® v11.0, released in May 2011, information physicians receive from colleague consults has the greatest influence on their clinical decisions, and healthcare provider portal sites have the broadest reach amongst online physicians. The study also shows that of the 24% of physicians already using online communities or social networks, 84% have visited Sermo in the last three months, more than three times the next largest competitor.

Sermo Sponsorship was designed to maximize the use of already-approved materials, making rollout of educational materials and resources for physicians simple, quick and cost effective. Sermo Sponsorship also allows targeting by specialty, ensuring relevancy and maximizing physician interest and engagement.

In addition to the Client Post product already available on Sermo, which allows companies to spark discussion directly with physicians, new sponsorship opportunities include:

  • Brand Pages – leverage existing materials to create a dedicated branded presence on Sermo consisting of useful educational tools and resources
  • Targeted Spotlights – direct the physicians you care about to Brand Pages using announcements interspersed throughout Sermo website
  • Mobile messaging – instantly alert and inform specialists about brand, product and company developments
  • Exclusivity – target specialists with your message on an exclusive basis for two- to four-week periods

"The Sermo Sponsorship product helped drive awareness of a major new oncology drug during the period immediately following the American Society of Clinical Oncology (ASCO) annual meeting," said Rich Westelman, Senior Vice President of Sales at Sermo.  "By choosing Sermo's online community, the brand brought its important new message to key influencers, during the most active, receptive time of the year."

About Sermo

Sermo is the largest online physician community in the United States, with over 120,000 physicians spanning 68 specialties.  All Sermo members are verified and credentialed physicians who collaborate on cases and exchange observations to improve patient care, discuss drugs and devices, and share information on new therapies and innovations. Sermo also provides a way to target and engage physicians by providing access to its community for clients that need fast, actionable insights into treatments, medications and devices.  For more information on Sermo Promotion visit www.sermo.com.


'/>"/>
SOURCE Sermo
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. LI-COR August 27th On-Line Webinar Introduces New Approach to Small Animal In Vivo Imaging
2. LUMEDX Introduces Advanced Multi-Modality, Multi-Vendor, Web-Enabled ECG Management Solution
3. McGraw-Hill Higher Education Introduces New Introductory Level Biology Content
4. Bruker Introduces HyperQuant™, a Unique Bench-Top NMR Reader to Quantify Hyperpolarization
5. OmniGuide Introduces The BeamPath Neuro(TM): A CO2 Laser Fiber for Brain And Spine Surgery
6. Pressure Cycling Technology (PCT) Highlighted in Five Podium Presentations at the Fifth International Conference on High Pressure; PBI Introduces the Patent-pending PCT Shredder at the Meeting
7. World Leader in Bench Top Flow Chemistry Instruments ThalesNano, Inc. Introduces an Industry First Seminar Series
8. SoluLinK Introduces New One-Shot ChromaLink(TM) Biotin Antibody Labeling Kit with Built-in Biotin Quantification.
9. LI-COR Introduces the Odyssey(R) Two-Color NIR Fluorescent Protein Molecular Weight Marker
10. China Biologic Products Enters Into Agreement to Acquire 35% Interest in Xian Huitian Blood Products Co., Ltd. and Introduces Preliminary Guidance for 2009
11. Nanoscience Instruments, Inc. Introduces All-Diamond AFM Probes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... 2017 Aethlon Medical, Inc. (Nasdaq: ... that validated the ability of the Aethlon Hemopurifier® to ... mortality in immune-suppressed sepsis patients and also contribute to ... objective of the study was to validate the ... (EBV) and Herpes Simplex virus 1 (HSV1) by the ...
(Date:2/22/2017)... SAN DIEGO , Feb. 22, ... (OTCQB:CELZ) announced today expansion of its translational research ... product through establishment of laboratory facilities in San ... the San Diego BioLabs facility, a biotechnology incubator ... and Sanofi. In November 2016, the ...
(Date:2/21/2017)... Feb. 21, 2017 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the ... results for the three months ended December 31, 2016. ... life sciences and diagnostics company that develops and commercializes proprietary ... ... build on the commercial milestones achieved in fiscal 2016," said ...
(Date:2/21/2017)... Basel, Switzerland (PRWEB) , ... February 21, 2017 ... ... for biopharmaceutical and biotech research and development (R&D), today announced the establishment of ... headed by Managing Director Kevin Teburi, a recognized expert in life science informatics. ...
Breaking Biology Technology:
(Date:2/2/2017)... Feb. 2, 2017   TapImmune, Inc. ... company specializing in the development of innovative peptide ... of cancer and metastatic disease, announced today it ... manufacturing of a second clinical lot of TPIV ... receptor alpha. The manufactured vaccine product will be ...
(Date:1/30/2017)...   Invitae Corporation (NYSE: NVTA ... today announced that it will report its fourth quarter ... on Monday, February 13, 2017, and Invitae,s management team ... p.m. Eastern / 1:45 p.m. Pacific. ... financial results, guidance, and recent developments and will spend ...
(Date:1/24/2017)... PHILADELPHIA , Jan. 24, 2017  It ... a baby,s sock that monitors vital signs and ... instance, an infant,s oxygen saturation level drops. But ... undue alarm to parents, with no evidence of ... "These devices are marketed aggressively to parents of ...
Breaking Biology News(10 mins):